China Medical Technologies, Inc (in Liquidation) and Others v. Wu Xiaodong and Others

Read the full judgment text of HCA 3391/2016 on BabelCite. This High Court CFI judgment was delivered on 16 October 2025.

1. On the third day of the trial, an issue arose during counsel’s oral opening submissions as to whether the 6 th Defendant can raise a factual point during the trial and whether such a point needs to be pleaded. The issue arose in this way.

Cited by 1 case · Cites 2 cases

Case No.HCA 3391/2016[2025] HKCFI 4997
Court
High Court CFI
Date16 Oct 2025
Judge
Case Document
100%Judiciary

HCA 3391/2016 & HCA 1417/2013

[2025] HKCFI 4997

HCA 3391/2016

IN THE HIGH COURT OF THE

HONG KONG SPECIAL ADMINISTRATIVE REGION

COURT OF FIRST INSTANCE

ACTION NO 3391 OF 2016

_______________

BETWEEN

  CHINA MEDICAL TECHNOLOGIES, INC.
(IN LIQUIDATION)
1st Plaintiff
  CMED TECHNOLOGIES LTD 2nd Plaintiff
  COSIMO BORRELLI AND YUEN LAI YEE
IN THEIR CAPACITY AS THE JOINT AND
SEVERAL LIQUIDATORS OF CHINA MEDICAL
TECHNOLOGIES, INC. (IN LIQUIDATION)
3rd Plaintiffs

and

  WU XIAODONG 1st Defendant
  SAMSON TSANG TAK YUNG 2nd Defendant
  CHEN ZHONG 3rd Defendant
  ZHU FENG (CHARLES) 4th Defendant
  CHONG WING HIP (IN HIS PERSONAL
CAPACITY AND FORMERLY TRADING AS
KAM HING TRADING CO)
5th Defendant
  HAO XIAOQING ALLAN 6th Defendant
  SUPREME WELL INVESTMENTS LIMITED 7th Defendant
  EAST HOPE INTERNATIONAL LIMITED 8th Defendant
  CHEER LINK INTERNATIONAL LIMITED 9th Defendant
  INNOVATIVE TECHNOLOGY INVESTMENT LIMITED 10th Defendant
  DYNAMIC SENSE LIMITED 11th Defendant
  TIME REGION HOLDINGS LIMITED 12th Defendant
  BI XIAOQIONG (IN HER PERSONAL CAPACITY
AND AS TRUSTEE OF THE XIAO QIONG BI
TRUST AND THE ALISA WU IRREVOCABLE
TRUST)
13th Defendant
  WORLDPRO INVESTMENTS LIMITED 14th Defendant
  LONG CHART INVESTMENTS LIMITED 15th Defendant
  CHAVIS INVESTMENTS LIMITED 16th Defendant
  SINOWELL INTERNATIONAL INVESTMENT LIMITED 17th Defendant
  CHENGXUAN INTERNATIONAL LTD 18th Defendant
  WEIXIAO MEDICAL TECHNOLOGY LIMITED 19th Defendant
  WB INTERNATIONAL HOLDING PTE LTD 20th Defendant
  MAX PROSPER ENTERPRISES LIMITED 21st Defendant
  JUN YUN BI 22nd Defendant
  GLOBAL FLASH LIMITED 23rd Defendant

_______________

AND

HCA 1417/2013

IN THE HIGH COURT OF THE

HONG KONG SPECIAL ADMINISTRATIVE REGION

COURT OF FIRST INSTANCE

ACTION NO 1417 OF 2013

_______________

BETWEEN

  CHINA MEDICAL TECHNOLOGIES, INC.
(IN LIQUIDATION)
Plaintiff

and

  WU XIAODONG 1st Defendant
  SAMSON TSANG TAK YUNG 2nd Defendant
  CHEN ZHONG 3rd Defendant
  ZHU FENG (CHARLES) 4th Defendant
  SUPREME WELL INVESTMENTS LIMITED 5th Defendant

_______________

(Consolidated by Order of Master Chow dated the 23rd day of July 2018)

Before: Hon Eugene Fung J in Court
Date of Hearing: 16 October 2025
Date of Decision: 16 October 2025

__________________

D E C I S I O N

__________________


1.On the third day of the trial, an issue arose during counsel’s oral opening submissions as to whether the 6th Defendant can raise a factual point during the trial and whether such a point needs to be pleaded. The issue arose in this way.

2.In this trial, one of the issues to be determined is whether the Plaintiffs’ claims are time-barred. In order to overcome the time bar defence raised by the 6th Defendant, the Plaintiffs rely on section 26 of the Limitation Ordinance (Cap 347) to postpone the commencement of the limitation period. Specifically, the Plaintiffs have pleaded that they could not, with reasonable diligence, discovered the fraud of the 6th Defendant before 23 or 24 December 2013. According to the Plaintiffs, that was the date when the Plaintiffs obtained the relevant banking documents and discovered that the 2nd Defendant was on both sides of the relevant transactions.

3.In their written opening dated 15 September 2025, Mr Kerby Lau and Mr Paul Law on behalf of the 6th Defendant submitted that “the Alleged Theft and/or the relevant facts of the case against D6 clearly could have been discovered by Ps much earlier by 2009 at the latest, even before liquidators were appointed”. Subsequent to the receipt of the document, I understand that the Plaintiffs’ solicitors wrote to the 6th Defendant’s solicitors and complained that this was an unpleaded case.

4.At the end of his oral submission on the third day of the trial, Mr Charles Manzoni SC on behalf of the Plaintiffs submitted that the 6th Defendant should not be allowed to raise the unpleaded case now because significant prejudice will be caused to the Plaintiffs. He also lay down the marker that the Plaintiffs will object if their factual witnesses are cross-examined during the trial for the purpose of advancing the 6th Defendant’s unpleaded case.

5.In his oral opening submission and when dealing with the Plaintiffs’ pleading objection, Mr Lau confirmed that the 6th Defendant does intend to argue that the Plaintiffs could have discovered the fraud on a date much earlier, and that he will cross-examine the Plaintiffs’ factual witnesses on this point. But he disagreed that this point needs to be pleaded.

(1) First, he submitted that the burden falls on the Plaintiffs to show that they could not with reasonable diligence have discovered the fraud. He said the 6th Defendant has put them to strict proof, and the 6th Defendant does not need to prove anything.

(2) Further, Mr Lau argued that the Plaintiffs have included in the trial bundles some documents for the purpose of showing that they could not have discovered the fraud with reasonable diligence, and the 6th Defendant must be allowed to test the Plaintiffs’ case by suggesting some earlier dates or events.

(3) Moreover, Mr Lau suggested that the Plaintiffs must have known that this point would be taken against them because the very same point appeared in a striking out decision in a different action by the Plaintiffs against the Bank of China.

(4) Finally, Mr Lau urged the court not to make a hasty decision to rule on the pleading point now and should instead hear all the evidence on a de bene esse basis before coming to a final view.

6.For the reasons that I am about to give, I am unable to agree with the 6th Defendant’s submissions that the new point does not need to be pleaded.

7.First, it is clear that the 6th Defendant’s current pleading simply contains a bare denial on the application of s.26(1)(a) of the Limitation Ordinance, and puts the Plaintiffs to strict proof that they could not with reasonable diligence have discovered the 6th Defendant’s alleged fraudulent, dishonest or unconscionable conduct sooner than they did. This appears in paragraph 59 of the 6th Defendant’s Amended Defence. Under RHC O.18 r.13(5), where an allegation made in a statement of claim is traversed by a denial, the party who denies the allegation shall in his defence (a) state his reasons for doing so and (b) if he intends to put forward a different version of events from that given by the plaintiff, state his own version. Accordingly, if the 6th Defendant wishes to suggest that the Plaintiffs could have discovered the fraud on a date much earlier than their pleaded date of 23 December 2013, the 6th Defendant must state his own version of when he says the Plaintiffs could have discovered the fraud. As noted in Hong Kong Civil Procedure 2025 vol 1 at Note 18/13/12, if a party fails to plead his own version, he will be taken not to have put forward any positive case in defence and will not be entitled to call any evidence of fact contrary to or inconsistent with the plaintiff’s pleaded contention.

8.Second, by suggesting that the Plaintiffs could have discovered the fraud on a date much earlier than their pleaded date of 23 December 2013, the 6th Defendant would have gone beyond merely testing the Plaintiffs’ case. In my view, testing the Plaintiffs’ case on s.26 may involve the 6th Defendant showing, for example, that the Plaintiffs did not obtain the relevant banking documents on 23 December 2013, or that such documents did not reveal the 2nd Defendant’s role in the relevant transactions. But the advancement of suggestions that the Plaintiffs could have discovered the fraud earlier than 23 December 2013 would constitute a positive case on the part of the 6th Defendant, and would need to be pleaded.

9.As far as the documents in the trial bundles identified by the 6th Defendant are concerned, they are minutes and notes of meetings and were included in Annexure 2 to Dr Crum’s witness statement. It is important to see what Dr Crum said in his witness statement as to why the various minutes and notes of meetings were referred to. Annexure 2 is referred to at paragraph 19.7 of Dr Crum’s witness statement. It appears from paragraph 19 that the purpose of referring to such meeting minutes and notes is to illustrate the general practice of the Board and Committee meetings of the 1st Plaintiff. Contrary to Mr Lau’s suggestion, it does not appear that the purpose of including the documents in Annexure 2 is to show that the Plaintiffs could not have discovered the fraud with reasonable diligence.

10.Third, the fact that a similar point was taken by the Bank of China against the Plaintiffs in a different action does not mean that the Plaintiffs must have known or anticipated that one of the Defendants in this action will take the same point in this trial. As pointed out by Mr Manzoni, the Bank of China expressly pleaded the point in its defence. If the point is not pleaded by any of the Defendants in these proceedings, there is no reason for the Plaintiffs to expect that the point would be taken against them at the trial.

11.Fourth, as Ma CJ said in Kwok Chin Wing v 21 Holdings Ltd (2013) 16 HKCFAR 663 at [21], “[i]t is the pleadings that will define the issues in a trial and dictate the course of proceedings both before and at trial. Where witnesses are involved, it will be the pleaded issues that define the scope of the evidence, and not the other way round. In other words, it will not be acceptable for unpleaded issues to be raised out of the evidence which is to be or has been adduced.” It is therefore wholly inappropriate for the trial judge to allow evidence to be adduced on an unpleaded issue first, even on a de bene esse basis, and then to decide on whether the unpleaded issue can be advanced at the end of the trial.

12.Finally, I accept Mr Manzoni’s submission that allowing the 6th Defendant to advance the point would cause significant prejudice to the Plaintiffs. It was pointed out that pursuant to the discovery protocol ordered by Ng J on 10 May 2019, the Plaintiffs have not disclosed any documents in these proceedings in relation to the engagement of the different professional advisers of the 1st Plaintiff, or the advice they gave. And the Plaintiffs have also been deprived of the opportunity to investigate the extent to which the various advisers might or might not have made the alleged fraud of the 6th Defendant discoverable, and adduce any form of evidence in these proceedings to rebut the unpleaded point.

13.For these reasons, I rule that the 6th Defendant is not permitted to contend in this trial that the Plaintiffs could have discovered the alleged fraud of the 6th Defendant earlier than 23 December 2013.

14.It is right to record that the 6th Defendant’s Amended Defence was not settled by either Mr Lau or Mr Law. Both of them were only instructed shortly before the trial commenced. They have tried to take the point as far as they possibly can, but the point is simply not open to the 6th Defendant to take on the existing pleading.

  (Eugene Fung)
  Judge of the Court of First Instance
  High Court

Mr Charles Manzoni SC and Ms Cherry Xu, instructed by Karas So LLP, for the 1st to 3rd Plaintiffs

The 3rd Defendant appeared in person

Mr Kerby Lau and Mr Paul Law, instructed by Li & Partners, for the 6th Defendant

Mr Benjamin Lam, instructed by Guantao & Chow Solicitors and Notaries, for the 13th Defendant

The 1st, 2nd, 4th, 5th, 7th to 12th, 14th to 23rd Defendants were not represented and did not appear

Other Judgments in This Case

Further hearings and rulings under HCA 3391/2016

China Medical Technologies, Inc.(in Liquidation) and Others v. Wu Xiaodong and Others
High Court CFI22 May 2019
China Medical Technologies, Inc. (in Liquidation) v. Wu Xiaodong and Others
High Court CFI22 May 2019
China Medical Technologies, Inc. (in Liquidation) and Others v. Wu Xiaodong and Others
High Court CFI17 Jun 2019
China Medical Technologies, Inc. (in Liquidation) and Others v. Wu Xiaodong and Others
High Court CFI19 Jul 2019
China Medical Technologies, Inc. (in Liquidation) v. Wu Xiaodong and Others
High Court CFI19 Jul 2019
China Medical Technologies, Inc (in Liquidation) and Others v. Wu Xiaodong and Others
High Court CFI10 Dec 2019
China Medical Technologies, Inc. (in Liquidation) v. Wu Xiaodong and Others
High Court CFI10 Dec 2019
China Medical Technologies, Inc (in Liquidation) and Others v. Wu Xiaodong and Others
High Court CFI03 Feb 2021
China Medical Technologies, Inc (in Liquidation) and Others v. Wu Xiaodong and Others
High Court CFI21 Oct 2022
China Medical Technologies, Inc. (in Liquidation) v. Wu Xiaodong and Others
High Court CFI21 Oct 2022
China Medical Technologies, Inc (in Liquidation) and Others v. Wu Xiaodong and Others
High Court CFI11 May 2023
China Medical Technologies, Inc. (in Liquidation) v. Wu Xiaodong and Others
High Court CFI11 May 2023
China Medical Technologies, Inc (in Liquidation) and Others v. Wu Xiaodong and Others
High Court CFI26 Jul 2023
China Medical Technologies, Inc. (in Liquidation) v. Wu Xiaodong and Others
High Court CFI26 Jul 2023
China Medical Technologies, Inc (in Liquidation) and Others v. Wu Xiaodong and Others
High Court CFI15 Sep 2023
China Medical Technologies, Inc. (in Liquidation) v. Wu Xiaodong and Others
High Court CFI15 Sep 2023
China Medical Technologies, Inc (in Liquidation) and Others v. Wu Xiaodong and Others
High Court CFI27 Oct 2023
China Medical Technologies, Inc. (in Liquidation) v. Wu Xiaodong and Others
High Court CFI27 Oct 2023
china Medical Technologies, Inc. (in Liquidation) v. Wu Xiaodong and Others
High Court CFI30 Jan 2024
China Medical Technologies, Inc (in Liquidation) and Others v. Wu Xiaodong and Others
High Court CFI17 Sep 2025
China Medical Technologies, Inc. (in Liquidation) v. Wu Xiaodong and Others
High Court CFI17 Sep 2025
China Medical Technologies, Inc. (in Liquidation) v. Wu Xiaodong and Others
High Court CFI16 Oct 2025
China Medical Technologies, Inc and Others v. Wu Xiaodong and Others
High Court CFI16 Jan 2026
China Medical Technologies, Inc. (in Liquidation) v. Wu Xiaodong and Others
High Court CFI16 Jan 2026